Paradigm Biocapital Advisors LP Arcellx, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.14 Billion
- Q2 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Arcellx, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 4,649,016 shares of ACLX stock, worth $339 Million. This represents 14.29% of its overall portfolio holdings.
Number of Shares
4,649,016
Previous 4,492,032
3.49%
Holding current value
$339 Million
Previous $295 Million
3.89%
% of portfolio
14.29%
Previous 15.1%
Shares
11 transactions
Others Institutions Holding ACLX
# of Institutions
218Shares Held
49.1MCall Options Held
245KPut Options Held
885K-
Vanguard Group Inc Valley Forge, PA3.94MShares$287 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$273 Million20.45% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$256 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.04MShares$221 Million4.37% of portfolio
-
Vestal Point Capital, LP New York, NY2.75MShares$200 Million9.53% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.19B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...